It funds innovation in different "missions" (environment and energy, healthcare, education, digital, space, and oceans),[1] with the goal of bringing "Europe in a leadership position in breakthrough technologies".
[5] As of 2024[update], JEDI was funding the projects of over 6,000 researchers in 29 countries across Europe and the world.
It is operated independently from any European governments with funding from foundations, companies, individuals and public institutions.
[9] The competition consisted in screening "billions of molecules with blocking interactions on SARS-CoV-2" to develop a drug against the coronavirus — with each participant having to use at least three different calculation methods for the simulations.
A paper published in Nature showed that the protein PDB 6W9C was one of the most used in silico drug design against Covid-19.